MedTrace Logo

Topical Calcipotriol /Betamethasone Ointment in the Treatment of Plaque Psoriasis

NCT06011083 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-08-25

No results posted yet for this study

Summary

comparing the clinical efficacy of topical ointment containing calcipotriol and betamethasone dipropionate used alone with the simultaneous use of fractional carbon dioxide laser and the same topical ointment containing these two ingredients as treatment modalities for plaque psoriasis. Additionally, looking into how both therapy modalities affect individuals with psoriasis in terms of how their quality of life is improved.

Conditions

  • Psoriasis Vulgaris
  • Fractional CO2 Laser

Interventions

DRUG

Topical Ointment containing Calcipotriol 0.05 mg/gm and Betamethasone dipropionate 0.5 mg/gm

using topical ointment containing calcipotriol and betamethasone dipropionate for plaque psoriasis.

DEVICE

Fractional carbon dioxide (CO2) laser

fractional CO2 laser sessions once per month for 3 months over a similar psoriatic plaque

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-02-28
Completion
2023-08-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06011083 on ClinicalTrials.gov